PNK-007

BIOLOGICAL2 trials

Sponsors

Celularity Incorporated

Conditions

Leukemia, Myeloid, AcuteMultiple Myeloma

Phase 1

A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML)

TerminatedNCT02781467

Celularity IncorporatedLeukemia, Myeloid, Acute

Start: 2016-07-11End: 2017-12-07Updated: 2020-07-22

A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)

CompletedNCT02955550

Celularity IncorporatedMultiple Myeloma

Start: 2017-01-05End: 2019-06-04Updated: 2020-07-22

Related Papers

Immune Monitoring of CD34+ Placental Cell Derived Natural Killer Cell Therapy (PNK-007) in Phase I Study of Multiple Myeloma

Blood2019-11-131 citations

Abstract CT079: A Phase I study of PNK-007, allogeneic, off the shelf NK cell in relapsed/refractory AML (NCT02781467)

Cancer Research2019-07-016 citations

Abstract CT079: A Phase I study of PNK-007, allogeneic, off the shelf NK cell in relapsed/refractory AML (NCT02781467)

Clinical Trials2019-07-012 citations

Abstract CT108: A Phase I study of PNK-007, allogeneic, off the shelf NK cell, post autologous transplant in multiple myeloma (NCT02955550)

Cancer Research2019-07-011 citations

Abstract CT108: A Phase I study of PNK-007, allogeneic, off the shelf NK cell, post autologous transplant in multiple myeloma (NCT02955550)

Clinical Trials2019-07-011 citations